Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma

Completed · Phase 1

Conditions studied: Multiple Myeloma

In brief

The primary goal of the study is to determine the best dose of an investigational drug to give to patients with multiple myeloma and to evaluate the investigational drug's effectiveness as a treatment for multiple myeloma.

Key facts

Study ID

NCT00036140

Run by

Pfizer

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Eligible patients must be at least 18 years of age with a diagnosis of multiple myeloma including elevated M-blood/urine protein or a tumor that can be evaluated by the doctor during the investigational drug's treatment.
• The patient's multiple myeloma must have gotten worse during/after previous chemotherapy was given.
• Any side-effects from prior chemotherapy must have subsided
• Blood and urine tests must show adequate bone marrow, liver, and kidney function.

You may not qualify if…

• Any of the following will exclude patients from study participation:
• indolent or smoldering myeloma or localized plasmacytoma
• hyperviscosity syndrome
• irradiation to 25% or more of bone marrow
• prior high dose chemotherapy with bone marrow or stem cell support
• current participation in other clinical trials
• pregnant or breast-feeding women
• known HIV-positive or AIDS-related illness
• patients planning to have radiation therapy or surgery that would interrupt study therapy in the next 6 months.

Where it is running

• Research Center — Los Angeles, California, United States
• Research Center — Los Angeles, California, United States
• Research Center — Rancho Mirage, California, United States
• Research Center — Cleveland, Ohio, United States
• Research Center — Marshfield, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.